| Subject: | FDA Approves New Treatment for Uterine Fibroids |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 17 Nov 2004 - 10:00 am |
| The FDA has announced approval of a new medical device for non-invasive treatment of uterine fibroids. The device is called ExAblate 2000 and was developed by InSightec. The ExAblate 2000 uses MRI guided focused ultrasound to heat and destroy the only fibroid tumor cells, leaving healthy tissue unharmed. MRI images locate the tumor, size and shape and monitor the temperature changes inside the patient's body while the focused ultrasound beam heats and destroys the tumor tissue. The treatment is... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
